Partnership
Alector Opts for Lonza’s Ibex™ Develop to Secure Future Manufacturing for Neurodegeneration Therapies
Lonza
PR-M05-19-NI-032May 10, 2019
Drug Designation
Alector Receives Orphan Drug Designation from the U.S. FDA for AL001 for the Treatment of Frontotemporal Dementia
Alector
PR-M08-18-NI-080Aug 21, 2018